Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05549323 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05549323 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 44 participants.
The verdict
NCT05549323, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
Interventions
- DRUG Placebo
- DRUG PF-07054894
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2025-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05549323
The ClinicalTrials.gov registry entry for NCT05549323 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05549323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05549323 about?
NCT05549323 is a clinical study titled "A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis". This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
What is the current status of trial NCT05549323?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-11-07. Estimated completion is 2025-11-11.
What interventions are being tested in trial NCT05549323?
The interventions under investigation include: Placebo (DRUG), PF-07054894 (DRUG).
Who is sponsoring clinical trial NCT05549323?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.